← SynDRA
EPROSARTAN
SynDRA canonical compound SYN0001983 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · OTC |
| Primary target(s) | AGTR1 |
| Mechanism of action | angiotensin receptor antagonist |
| Indication | hypertension |
| Disease area | cardiology |
All known targets
Mechanisms of action (all sources)
- AGTR1 ANTAGONIST
- Type-1 angiotensin II receptor antagonist
- angiotensin receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCC3
- HTR2C
- MC3R
- MAOA
- KCNH2
- HTR7
- HTR6
- HTR5A
- HTR3A
- HTR2B
- MLNR
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HDAC6
- GIPR
- MC4R
- ABCC2
- GHSR
- PGR
- TACR2
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- PTGS2
- PDE6A
- NPY2R
- PDE4D
- PDE3A
- OPRM1
- OPRK1
- OPRD1
- NTSR1
- NR3C1
- NPY1R
- GCGR
Drug classes
- Angiotensin 2 Receptor Antagonists
- Angiotensin 2 Receptor Blocker
- Angiotensin II Type 2 Receptor Blockers
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Cardiovascular Agents
ATC classes
- C09C · ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
- ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Cross-references
Synonyms
- EPROSARTAN MESYLATE
- TEVETEN
- TEVETEN HCT
- SKF-108566
- eprosartan mesylate
- eprosartan mesilate
- SK&F-108566
- SK-108566
- Teveten
- F 108566
- UNII-2KH13Z0S0Y
- CHEMBL813
- 2KH13Z0S0Y
- CHEBI:4814
- Teveten (TN)
- Eprosartan (USAN/INN)
- Eprosartan [USAN:BAN:INN]
- (4-carboxybenzyl)imidazole-5-acrylic acid
- [3H]eprosartan
- [3H]-eprosartan
- NCGC00164557-01
- Eprozar
- Eprosartan [USAN:INN:BAN]
- SR-05000001450
- HSDB 7521
- [3H]SK&F 108566
- EPROSARTAN [MI]
- EPROSARTAN [INN]
- EPROSARTAN [HSDB]
- EPROSARTAN [USAN]
- EPROSARTAN [VANDF]
- SCHEMBL4025
- EPROSARTAN [WHO-DD]
- GTPL588
- BIDD:GT0030
- GTPL3940
- DTXSID0022989
- CHEBI:94094
Reported adverse events
- Dizziness
- Headache
- Back pain
- Fatigue
- Hypersensitivity
- Leukopenia
- Myalgia
- Neutropenia
- Sinusitis
- Stevens-Johnson syndrome
- Thrombocytopenia
Look up EPROSARTAN in the interactive SynDRA portal →